A ranar 24 ga Afrilu, 2025, GenFleet Therapeutics ta sanar da cewa Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da sabon amfani da maganin GFH375/VS-7375, wani maganin hana KRAS G12D (ON/OFF) da ake sha a baki, don gwajin asibiti da ke kula da marasa lafiya da suka kamu da ciwon daji da ke ɗauke da maye gurbin KRAS G12D. An shirya cewa za a fara binciken ne ta hannun abokin hulɗar GenFleet Verastem Oncology a Amurka a tsakiyar shekarar 2025. Binciken farko da aka yi a cikin ɗan adam na GFH375 wanda GenFleet ya fara a China ya ci gaba zuwa mataki na biyu kuma an zaɓi bayanan farko na inganci da aminci na wannan binciken a cikin gabatarwar baki cikin sauri a taron shekara-shekara na Ƙungiyar Kula da Cututtukan ...
Sunadaran RAS, a cikin nau'in GTP mai ɗaurewa ko mara aiki, su ne maɓallan ƙwayoyin halitta masu sarrafa martanin ƙwayoyin halitta a cikin hanyoyin sigina ciki har da RAS-RAF-MEK-ERK da PI3K/AKT/mTOR. Kwayoyin halittar RAS guda uku da ke ɓoye don isoforms na furotin, wato Kirsten Ras (KRAS), Harvey Ras (HRAS) da Neuroblastoma Ras (NRAS), kuma KRAS ita ce oncogene da aka fi canzawa a cikin mutane. Daga cikin maye gurbi na KRAS, G12D, G12V, da G12C suna wakiltar manyan kwayoyin halitta guda uku da aka fi canzawa. Sauyewar KRAS G12D galibi ana samunta a cikin adenocarcinoma na pancreas, ciwon daji na hanji, da adenocarcinoma na huhu.
Ana samun yawancin marasa lafiya da ke ɗauke da maye gurbin KRAS G12D ba tare da tarihin shan taba ba kuma ba su da isasshen amsawa ga masu hana PD-1. Masu hana G12D masu zaɓin maye gurbi suna da alƙawarin amfanar da manyan sassan marasa lafiya PDAC da KRAS ke jagoranta tunda canje-canjen KRAS G12D sune canje-canjen da suka fi faruwa a cikin marasa lafiya PDAC (kimanin kashi 40%) waɗanda aka ruwaito suna da jimillar adadin rayuwa na shekaru 5 ƙasa da kashi 10%.
GFH375 wani ƙaramin ƙwayar halitta ne mai aiki da baki, mai ƙarfi, mai zaɓe sosai wanda aka ƙera don kai hari ga musayar GTP/GDP, ta haka yana katse kunna hanyoyin da ke ƙasa da kuma hana yaduwar ƙwayoyin ƙari yadda ya kamata. Nazarin asibiti ya nuna hanawa dangane da kashi a cikin samfuran da ke ɗauke da maye gurbin KRAS G12D; GFH375 ya kuma nuna ƙarancin haɗarin da ba a kai hari ba a cikin zaɓin kinase da gwaje-gwajen manufa ta aminci.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Afrilu-25-2025